← ANALYST RATINGS · TIPRANKS
Harmony Biosciences Holdings (HRMY): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy2 Hold1 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $46.00, the highest $60.00, the lowest $30.00. The average is +21.2% from the last price of $37.95.
Analyst ratings 17
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Caroline Palomeque★★★★★★★★★★#12154 · hits 31% · avg −11.1% | Ladenburg Thalmann & Co. | $55.00 | Buy | +44.9% | Initiated | 15.10.26on TipRanks 07:50 | +1.7%next day +0.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $41.00 → $43.00+4.9% | Buy | +13.3% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $42.00 → $43.00+2.4% | Buy | +13.3% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $41.00 → $43.00+4.9% | Buy | +13.3% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $39.00 → $43.00+10.3% | Buy | +13.3% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $41.00 → $44.00+7.3% | Buy | +15.9% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $42.00 → $43.00+2.4% | Buy | +13.3% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $55.00 | Buy | +44.9% | Reiterated | 13.10.26on TipRanks 06:26 | −3.1%next day +2.4% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $51.00 | Buy | +34.4% | Reiterated | 12.10.26on TipRanks 10:25 | −5.0%next day −3.1% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $30.00 | Sell | −20.9% | Reiterated | 12.10.26on TipRanks 08:25 | −5.0%next day −3.1% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $39.00 → $42.00+7.7% | Hold | +10.7% | Reiterated | 01.10.26on TipRanks 09:08 | +0.6%next day −0.6% · 5 days −1.2% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $51.00 | Buy | +34.4% | Reiterated | 25.09.26on TipRanks 13:31 | −0.3%next day −2.3% · 5 days −3.7% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $50.00 | Buy | +31.8% | Reiterated | 24.09.26on TipRanks 06:08 | +1.8%next day −0.3% · 5 days −3.4% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $60.00 | Buy | +58.1% | Initiated | 26.08.26on TipRanks 07:21 | +1.8%next day −0.1% · 5 days +8.2% | ↗ |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $55.00 | Buy | +44.9% | Reiterated | 12.08.26on TipRanks 06:15 | +0.4%next day −3.9% · 5 days +0.8% | ↗ |
| So Youn Shim | UBS | $33.00 → $37.00+12.1% | Hold | −2.5% | Reiterated | 05.08.26on TipRanks Aug 19 21:04 | −1.2%next day +1.5% · 5 days +3.6% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $36.00 → $39.00+8.3% | Hold | +2.8% | Assigned | 05.08.26on TipRanks 09:25 | −1.2%next day +1.5% · 5 days +3.6% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | $29.00 → $34.00+17.2% | Hold | −10.4% | Reiterated | 05.08.26on TipRanks 07:55 | −1.2%next day +1.5% · 5 days +3.6% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $28.00 → $30.00+7.1% | Sell | −20.9% | Reiterated | 04.08.26on TipRanks Aug 5 04:50 | +7.1%next day −1.2% · 5 days +2.0% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $43.00 → $42.00−2.3% | Buy | +10.7% | Reiterated | 04.08.26on TipRanks 19:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $44.00 → $41.00−6.8% | Buy | +8.0% | Reiterated | 04.08.26on TipRanks 11:08 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $41.00 → $39.00−4.9% | Buy | +2.8% | Reiterated | 04.08.26on TipRanks 11:08 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $43.00 → $42.00−2.3% | Buy | +10.7% | Reiterated | 04.08.26on TipRanks 11:08 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $43.00 → $41.00−4.7% | Buy | +8.0% | Reiterated | 04.08.26on TipRanks 11:08 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $44.00 → $42.00−4.5% | Buy | +10.7% | Reiterated | 04.08.26on TipRanks 11:08 | — | |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $37.00 | Hold | −2.5% | Reiterated | 16.07.26on TipRanks Jul 17 08:36 | −3.4%next day +1.7% · 5 days +8.4% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $62.00 → $72.00+16.1% | Buy | +89.7% | Reiterated | 22.04.26on TipRanks 10:06 | −1.5%next day +0.7% · 5 days −2.9% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $46.00 | Buy | +21.2% | Reiterated | 22.04.26on TipRanks 07:06 | −1.5%next day +0.7% · 5 days −2.9% | ↗ |
| Andreas Argyrides★★★★★★★★★★#1658 · hits 46% · avg +10.2% | Chardan Capital | $62.00 | Buy | +63.4% | Reiterated | 25.02.26on TipRanks 08:15 | −0.8%next day +3.6% · 5 days +2.4% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Harmony Biosciences Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $44.00 at a price of $39.26 (+12.1%); now: $46.00 at $37.95 (+21.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 6 | 4 | 3 | 1 |
| Buy | 2 | 3 | 7 | 10 | 11 | 8 |
| Hold | 1 | 2 | 3 | 4 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 2 |
Earnings and sales forecast
Next report: 03.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.11 (from $0.86 to $1.54). Last quarter: $1.28.
Sales
Next quarter’s sales estimate — $274M (from $270M to $279M). Last quarter: $261M.
Best top-analyst consensus in the sector · Healthcare
About Harmony Biosciences Holdings
- CEO: Jeffrey Dayno
- Employees: 293
- 630 West Germantown Pike, Plymouth Meeting, PA, 19462, US
- www.harmonybiosciences.com
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Data from the stock’s TipRanks forecast page, read 0 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗